Nonresectable Adrenocortical Carcinoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Nonresectable Adrenocortical Carcinoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (2 shown)

CompletedPhase 2

NCT00215202

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

The use of Iressa will result in a greater than 20% response rate in patients with nonresectable adrenocortical cancer who have previously been treated with one…

United States16 participantsStarted 2004-08

Treatment: Iressa (ZD1839)

WithdrawnPhase 2

NCT00469469

Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma

This is a Phase II study of intravenous Bevacizumab in patients with pathologically confirmed nonresectable primary adrenocortical cancer (ACC). Patients must h…

United States0Started 2007-05

Treatment: Bevacizumab